XML 82 R38.htm IDEA: XBRL DOCUMENT
v3.22.4

Other operating income | 12 Months Ended
--- | ---
Dec. 31, 2022
Analysis of income and expense [abstract] |
Other operating income | Other operating incomeOther operating income totaled €1,969 million in 2022, versus €859 million in 2021 and €697 million in 2020.Other operating income includes (i) gains from asset divestments, amounting to €655 million in 2022 (versus €418 million in 2021 and €307 million in 2020); and (ii) income from Sanofi’s pharmaceutical partners, amounting to €1,178 million in 2022 (including €1,147 million from Regeneron, see Note D.26. below and Note C.1.), compared with €245 million in 2021 and €199 million in 2020. For 2021, it includes a payment of €119 million from Daiichi Sankyo relating to the termination of a vaccines collaboration agreement in Japan

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration